Cargando…
Chemsex is not a barrier to self-reported daily PrEP adherence among PROUD study participants
BACKGROUND: Pre-exposure prophylaxis (PrEP) is a novel HIV prevention method whereby HIV-negative individuals take the drugs tenofovir and emtricitabine to prevent HIV acquisition. Optimal adherence is critical for PrEP efficacy. Chemsex describes sexual activity under the influence of psychoactive...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6913514/ https://www.ncbi.nlm.nih.gov/pubmed/31739177 http://dx.doi.org/10.1016/j.drugpo.2019.10.007 |
_version_ | 1783479652834082816 |
---|---|
author | O'Halloran, Charlotte Rice, Brian White, Ellen Desai, Monica Dunn, David T McCormack, Sheena Sullivan, Ann K. White, David McOwan, Alan Gafos, Mitzy |
author_facet | O'Halloran, Charlotte Rice, Brian White, Ellen Desai, Monica Dunn, David T McCormack, Sheena Sullivan, Ann K. White, David McOwan, Alan Gafos, Mitzy |
author_sort | O'Halloran, Charlotte |
collection | PubMed |
description | BACKGROUND: Pre-exposure prophylaxis (PrEP) is a novel HIV prevention method whereby HIV-negative individuals take the drugs tenofovir and emtricitabine to prevent HIV acquisition. Optimal adherence is critical for PrEP efficacy. Chemsex describes sexual activity under the influence of psychoactive drugs, in the UK typically; crystal methamphetamine, gamma-hydroxybutyrate(GHB) and/or mephedrone. Chemsex drug use has been associated with increased HIV transmission risk among gay, bisexual and other men who have sex with men (GBM) and poor ART adherence among people living with HIV. This study assessed whether self-reported chemsex events affected self-reported daily PrEP adherence among PROUD study participants. METHODS: The PROUD study was an open-label, randomised controlled trial, conducted in thirteen English sexual health clinics, assessing effectiveness of Truvada(Ⓡ)-PrEP among 544 HIV-negative GBM. The study reported an 86% risk-reduction of HIV from daily PrEP. Participants were asked about chemsex engagement at follow-up visits. Monthly self-reports of missed PrEP tablets were aggregated to assess adherence between visits. Univariable and multivariable regression analyses were performed to test for associations between chemsex and reporting less than seven out of seven intended doses(<7/7ID) in the 7 days before and/or after last condomless anal intercourse(CAI). RESULTS: 1479 follow-up visit forms and 2260 monthly adherence forms from 388 participants were included in the analyses, with 38.5% visit forms reporting chemsex since last visit and 29.9% follow-up periods reporting <7/7ID. No statistically significant associations were observed between reporting <7/7ID and chemsex (aOR=1.29 [95% CI 0.90–1.87], p = 0.168). Statistically significant associations were seen between reporting <7/7ID and participants perceiving that they would miss PrEP doses during the trial, Asian ethnicity, and reporting unemployment at baseline. CONCLUSIONS: These analyses suggest PrEP remains a feasible and effective HIV prevention method for GBM engaging in chemsex, a practise which is prevalent in this group and has been associated with increased HIV transmission risk. |
format | Online Article Text |
id | pubmed-6913514 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-69135142019-12-23 Chemsex is not a barrier to self-reported daily PrEP adherence among PROUD study participants O'Halloran, Charlotte Rice, Brian White, Ellen Desai, Monica Dunn, David T McCormack, Sheena Sullivan, Ann K. White, David McOwan, Alan Gafos, Mitzy Int J Drug Policy Article BACKGROUND: Pre-exposure prophylaxis (PrEP) is a novel HIV prevention method whereby HIV-negative individuals take the drugs tenofovir and emtricitabine to prevent HIV acquisition. Optimal adherence is critical for PrEP efficacy. Chemsex describes sexual activity under the influence of psychoactive drugs, in the UK typically; crystal methamphetamine, gamma-hydroxybutyrate(GHB) and/or mephedrone. Chemsex drug use has been associated with increased HIV transmission risk among gay, bisexual and other men who have sex with men (GBM) and poor ART adherence among people living with HIV. This study assessed whether self-reported chemsex events affected self-reported daily PrEP adherence among PROUD study participants. METHODS: The PROUD study was an open-label, randomised controlled trial, conducted in thirteen English sexual health clinics, assessing effectiveness of Truvada(Ⓡ)-PrEP among 544 HIV-negative GBM. The study reported an 86% risk-reduction of HIV from daily PrEP. Participants were asked about chemsex engagement at follow-up visits. Monthly self-reports of missed PrEP tablets were aggregated to assess adherence between visits. Univariable and multivariable regression analyses were performed to test for associations between chemsex and reporting less than seven out of seven intended doses(<7/7ID) in the 7 days before and/or after last condomless anal intercourse(CAI). RESULTS: 1479 follow-up visit forms and 2260 monthly adherence forms from 388 participants were included in the analyses, with 38.5% visit forms reporting chemsex since last visit and 29.9% follow-up periods reporting <7/7ID. No statistically significant associations were observed between reporting <7/7ID and chemsex (aOR=1.29 [95% CI 0.90–1.87], p = 0.168). Statistically significant associations were seen between reporting <7/7ID and participants perceiving that they would miss PrEP doses during the trial, Asian ethnicity, and reporting unemployment at baseline. CONCLUSIONS: These analyses suggest PrEP remains a feasible and effective HIV prevention method for GBM engaging in chemsex, a practise which is prevalent in this group and has been associated with increased HIV transmission risk. Elsevier 2019-12 /pmc/articles/PMC6913514/ /pubmed/31739177 http://dx.doi.org/10.1016/j.drugpo.2019.10.007 Text en © 2019 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Article O'Halloran, Charlotte Rice, Brian White, Ellen Desai, Monica Dunn, David T McCormack, Sheena Sullivan, Ann K. White, David McOwan, Alan Gafos, Mitzy Chemsex is not a barrier to self-reported daily PrEP adherence among PROUD study participants |
title | Chemsex is not a barrier to self-reported daily PrEP adherence among PROUD study participants |
title_full | Chemsex is not a barrier to self-reported daily PrEP adherence among PROUD study participants |
title_fullStr | Chemsex is not a barrier to self-reported daily PrEP adherence among PROUD study participants |
title_full_unstemmed | Chemsex is not a barrier to self-reported daily PrEP adherence among PROUD study participants |
title_short | Chemsex is not a barrier to self-reported daily PrEP adherence among PROUD study participants |
title_sort | chemsex is not a barrier to self-reported daily prep adherence among proud study participants |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6913514/ https://www.ncbi.nlm.nih.gov/pubmed/31739177 http://dx.doi.org/10.1016/j.drugpo.2019.10.007 |
work_keys_str_mv | AT ohallorancharlotte chemsexisnotabarriertoselfreporteddailyprepadherenceamongproudstudyparticipants AT ricebrian chemsexisnotabarriertoselfreporteddailyprepadherenceamongproudstudyparticipants AT whiteellen chemsexisnotabarriertoselfreporteddailyprepadherenceamongproudstudyparticipants AT desaimonica chemsexisnotabarriertoselfreporteddailyprepadherenceamongproudstudyparticipants AT dunndavidt chemsexisnotabarriertoselfreporteddailyprepadherenceamongproudstudyparticipants AT mccormacksheena chemsexisnotabarriertoselfreporteddailyprepadherenceamongproudstudyparticipants AT sullivanannk chemsexisnotabarriertoselfreporteddailyprepadherenceamongproudstudyparticipants AT whitedavid chemsexisnotabarriertoselfreporteddailyprepadherenceamongproudstudyparticipants AT mcowanalan chemsexisnotabarriertoselfreporteddailyprepadherenceamongproudstudyparticipants AT gafosmitzy chemsexisnotabarriertoselfreporteddailyprepadherenceamongproudstudyparticipants |